Home
Forums
New Posts
Illini Basketball
Illini Football
Sports Talk
Log in
Register
What's new
Menu
Log in
Register
Install the app
Install
Forums
General
Chat
Trading Stock/Investing
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="DaytonIllini" data-source="post: 964962"><p>I think you guys are thinking of "phase 1, 2, 3" as opposed to stage. I agree with what has been said otherwise. Right now Gilead is done with phase 3 trials on a multi drug cocktail that has ridiculous efficacy. Everyone is expecting FDA approval in the near term. There are some concerns. I believe J&J is in phase 3 trial on a competing regimen. Also with Sovaldi in large scale use it's possible that unforeseen side effects or complications could be found. </p><p></p><p>Often when everyone expects good news, it's baked into the price already. That said it isn't really priced for perfection. A 50% increase over 12 months is possible.</p></blockquote><p></p>
[QUOTE="DaytonIllini, post: 964962"] I think you guys are thinking of "phase 1, 2, 3" as opposed to stage. I agree with what has been said otherwise. Right now Gilead is done with phase 3 trials on a multi drug cocktail that has ridiculous efficacy. Everyone is expecting FDA approval in the near term. There are some concerns. I believe J&J is in phase 3 trial on a competing regimen. Also with Sovaldi in large scale use it's possible that unforeseen side effects or complications could be found. Often when everyone expects good news, it's baked into the price already. That said it isn't really priced for perfection. A 50% increase over 12 months is possible. [/QUOTE]
Verification
Post reply
Forums
General
Chat
Trading Stock/Investing
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…